Table 1.
Demographic characteristics and number of participants with available data on each of the laboratory abnormalities.
| Study | Region | Clinical Characteristics | No. with available laboratory data | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Age*** | Female sex |
Black Race |
DM | eGFR*** | albuminuria /proteinuria‡ |
Hb | K | Bicarb | PTH | Phos | Ca | HTN | ||
| CKD Cohorts | |||||||||||||||
| AASK | US | 1094 | 55 (11) | 39% | 100% | 0% | 46 (15) | 55% | 1066 | 984 | 1093 | 984 | 1094 | ||
| BC CKD | CA | 11880 | 71 (13) | 46% | 0% | 50% | 33 (16) | 72% | 11655 | 11785 | 11162 | 10075 | 11237 | 10966 | 11880 |
| CanPREDDICT | CA | 2061 | 68 (13) | 38% | 2% | 50% | 27 (9) | 74% | 2045 | 2052 | 1822 | 1900 | 1978 | 1956 | 2061 |
| CARE FOR HOMe | DE | 369 | 66 (13) | 43% | 0% | 89% | 49 (17) | 46% | 371 | 371 | 371 | 370 | 369 | ||
| CCF | US | 19249 | 72 (12) | 55% | 14% | 34% | 47 (14) | 29% | 12696 | 17498 | 16218 | 1758 | 3030 | 12923 | 19249 |
| CKD-JAC | JP | 2679 | 61 (12) | 38% | 0% | 32% | 37 (17) | 88% | 2639 | 2640 | 2670 | 2379 | 2413 | 2679 | |
| CRIB | UK | 375 | 62 (14) | 35% | 5% | 17% | 22 (11) | 84% | 364 | 373 | 324 | 316 | 360 | 374 | 375 |
| GCKD | DE | 5159 | 61 (12) | 40% | 0% | 36% | 49 (18) | 57% | 5127 | 5030 | 5160 | 5159 | 5159 | ||
| Geisinger CKD† | US | 24611 | 71 (12) | 56% | 1% | 64% | 46 (12) | 43% | 19008 | 24417 | 24358 | 7803 | 12879 | 1778 | 24611 |
| Gonryo | JP | 3009 | 63 (15) | 47% | 0% | 46% | 71 (32) | 52% | 3044 | 2278 | 2042 | 3009 | |||
| MASTERPLAN | NL | 670 | 60 (13) | 31% | 0% | 24% | 36 (15) | 72% | 670 | 670 | 668 | 638 | 670 | 669 | 670 |
| MDRD | US | 1736 | 51 (13) | 40% | 12% | 6% | 41 (21) | 74% | 1719 | 830 | 1725 | 1735 | 1725 | 1736 | |
| MMKD | Multi§ | 202 | 47 (12) | 34% | 0% | 0% | 47 (30) | 92% | 202 | 201 | 202 | 202 | 202 | ||
| Mt Sinai BioMe CKD† | US | 3521 | 63 (13) | 56% | 31% | 58% | 43 (13) | 50% | 1931 | 3518 | 3520 | 1538 | 1904 | 3112 | 3521 |
| PSP-CKD | UK | 9434 | 76 (11) | 59% | 2% | 36% | 50 (14) | 27% | 2223 | 9405 | 228 | 895 | 1462 | 9434 | |
| RCAV | US | 127812 | 69 (10) | 3% | 16% | 82% | 55 (15) | 44% | 108044 | 124843 | 119959 | 25507 | 98308 | 127812 | |
| RENAAL | Multi¶ | 1512 | 60 (7) | 37% | 15% | 100% | 39 (13) | 100% | 1510 | 1513 | 1510 | 1509 | 1512 | ||
| SCREAM CKD† | SE | 33232 | 65 (12) | 55% | 0% | 26% | 47 (12) | 31% | 30209 | 29383 | 7011 | 6850 | 9517 | 15330 | 33232 |
| SRR-CKD | SE | 3051 | 68 (15) | 33% | 0% | 38% | 25 (12) | 79% | 3032 | 2591 | 1613 | 2420 | 2975 | 2833 | 3051 |
| Sunnybrook | CA | 3010 | 61 (18) | 47% | 0% | 47% | 56 (31) | 59% | 2822 | 2965 | 2748 | 1415 | 2389 | 2426 | 3010 |
| Subtotal | 254666 | 69 (12) | 27% | 10% | 62% | 50 (17) | 44% | 209311 | 235549 | 192340 | 42985 | 88069 | 184328 | 254666 | |
| Gen Pop Cohorts | |||||||||||||||
| Aichi | JP | 4987 | 49 (7) | 20% | 0% | 9% | 100 (13) | 3% | 4987 | 4987 | |||||
| ARIC* | US | 11889 | 64 (6) | 56% | 23% | 18% | 86 (17) | 9% | 11889 | ||||||
| AusDiab* | AU | 11198 | 52 (14) | 55% | 0% | 8% | 86 (17) | 7% | 11198 | ||||||
| Beijing | CN | 1533 | 60 (10) | 50% | 0% | 29% | 83 (14) | 6% | 1530 | 1533 | |||||
| BIS | DE | 2055 | 80 (7) | 53% | 0% | 26% | 65 (17) | 26% | 1995 | 2048 | 2052 | 2055 | |||
| ChinaNS* | CN | 46810 | 47 (15) | 57% | 0% | 8% | 101 (18) | 12% | 46810 | ||||||
| CHS* | US | 2984 | 78 (5) | 59% | 17% | 18% | 66 (16) | 20% | 2984 | ||||||
| CIRCS | JP | 11916 | 54 (9) | 61% | 0% | 3% | 89 (15) | 3% | 11475 | 8034 | 11916 | ||||
| ESTHER* | DE | 9744 | 62 (7) | 55% | 0% | 19% | 87 (20) | 12% | 9744 | ||||||
| Framingham* | US | 2956 | 59 (10) | 53% | 0% | 8% | 88 (19) | 12% | 2956 | ||||||
| Gubbio | IT | 1684 | 54 (6) | 55% | 0% | 5% | 84 (12) | 4% | 1684 | 1684 | 1684 | 1684 | |||
| IPHS | JP | 97769 | 59 (10) | 66% | 0% | 3% | 86 (14) | 2% | 97740 | 97769 | |||||
| JMS | JP | 5124 | 54 (11) | 64% | 0% | 55% | 98 (15) | 2% | 5091 | 5124 | |||||
| KHS | KR | 243779 | 44 (10) | 33% | 0% | 5% | 88 (14) | 14% | 243716 | 108185 | 152742 | 224193 | 243779 | ||
| MESA* | US | 6796 | 62 (10) | 53% | 28% | 13% | 83 (16) | 10% | 6796 | ||||||
| MRC | UK | 12367 | 81 (5) | 61% | 0% | 8% | 57 (15) | 7% | 12101 | 11840 | 11334 | 12026 | 12367 | ||
| NHANES | US | 56017 | 47 (19) | 52% | 22% | 12% | 97 (25) | 12% | 51434 | 57208 | 41359 | 9774 | 57208 | 41405 | 56017 |
| NIPPON | JP | 10382 | 50 (13) | 56% | 0% | 3% | 84 (17) | 3% | 10382 | ||||||
| DATA80* | |||||||||||||||
| NIPPON DATA90 | JP | 7612 | 53 (14) | 58% | 0% | 5% | 94 (17) | 3% | 7612 | 7612 | |||||
| NIPPON | JP | 2749 | 59 (16) | 57% | 0% | 13% | 97 (17) | 3% | 2730 | 2749 | |||||
| DATA2010 | |||||||||||||||
| Ohasama | JP | 3300 | 60 (11) | 59% | 0% | 9% | 97 (13) | 6% | 1926 | 3300 | |||||
| PREVEND | NL | 8060 | 50 (13) | 50% | 1% | 4% | 96 (16) | 11% | 7319 | 7314 | 7319 | 7313 | 8060 | ||
| Rancho Bernardo | US | 1484 | 71 (12) | 60% | 0% | 14% | 66 (16) | 15% | 1484 | 1484 | 1484 | 1484 | |||
| REGARDS | US | 27727 | 65 (9) | 54% | 40% | 21% | 85 (20) | 15% | 19070 | 2700 | 1960 | 1347 | 27727 | ||
| RSIII | NL | 3519 | 57 (7) | 57% | 1% | 13% | 86 (14) | 6% | 3525 | 3375 | 3519 | ||||
| SEED* | SG | 7028 | 58 (10) | 49% | 0% | 29% | 86 (19) | 24% | 7028 | ||||||
| Taiwan MJ | TW | 501704 | 41 (14) | 51% | 0% | 5% | 89 (18) | 2% | 501646 | 159268 | 369932 | 369833 | 501704 | ||
| Takahata | JP | 3524 | 63 (10) | 55% | 0% | 8% | 98 (13) | 15% | 3523 | 1923 | 1923 | 1923 | 3524 | ||
| ULSAM | SE | 1123 | 71 (1) | 0% | 0% | 13% | 76 (11) | 16% | 894 | 1104 | 1089 | 1123 | |||
| Subtotal | 1107820 | 47 (15) | 49% | 3% | 7% | 89 (18) | 7% | 970255 | 358475 | 41359 | 20682 | 612113 | 662665 | 1107820 | |
| High Risk Cohorts | |||||||||||||||
| ADVANCE | Multi** | 11033 | 66 (6) | 43% | 0% | 100% | 78 (17) | 31% | 11033 | 11033 | |||||
| Geisinger | US | 65051 | 61 (15) | 52% | 2% | 62% | 80 (27) | 30% | 46072 | 64503 | 64341 | 51372 | 65051 | ||
| Maccabi | IL | 264255 | 57 (14) | 49% | 0% | 34% | 86 (21) | 16% | 253333 | 246712 | 19967 | 71310 | 153794 | 264255 | |
| Mt Sinai BioMe | US | 8109 | 56 (14) | 57% | 33% | 51% | 73 (28) | 35% | 4346 | 8044 | 8047 | 7240 | 8109 | ||
| NZDCS* | NZ | 31622 | 61 (14) | 50% | 0% | 100% | 76 (23) | 9% | 31622 | ||||||
| Pima | US | 5074 | 33 (14) | 56% | 0% | 27% | 120 (19) | 20% | 5058 | 5074 | |||||
| SCREAM | SE | 260047 | 48 (18) | 54% | 0% | 12% | 93 (24) | 11% | 232861 | 208611 | 12001 | 83703 | 260047 | ||
| SMART | NL | 3691 | 58 (13) | 29% | 0% | 25% | 77 (21) | 33% | 3684 | 3691 | |||||
| ZODIAC | NL | 1632 | 67 (12) | 56% | 0% | 100% | 68 (17) | 8% | 1153 | 1203 | 1154 | 1153 | 1632 | ||
| Subtotal | 650514 | 54 (17) | 51% | 1% | 33% | 88 (24) | 15% | 545354 | 540056 | 84389 | 21170 | 72464 | 297262 | 650514 | |
| Subtotal Gen Pop/High Risk | 1758334 | 50 (16) | 50% | 2% | 16% | 88 (20) | 10% | 1515609 | 898531 | 125748 | 41852 | 684577 | 959927 | 1758334 | |
| Total† | 1951875 | 1673772 | 1076762 | 283199 | 84837 | 772646 | 1122573 | 1951875 | |||||||
Expansions of study acronyms are provied in Item S2. DM: diabetes mellitus; HTN: hypertension; Hb: hemoglobin; K: potassium; PTH: parathyroid hormone; Phos: phosphorous; Ca: corrected calcium; DE, Germany; JP, Japan; UK, United Kingdom; USA, United States of America; CA, Canada; SE, Sweden, CN, China; AU, Australia; NL, Netherlands; KR, South Korea; IT, Italy; SG, Singapore; TW, Taiwan; IL, Israel; NZ, New Zealand; gen pop, general population
Studies with only HTN
CKD population from three administrative high risk cohorts, not included in the total N
Defined as urinary albumin-creatinine ratio ≥30 mg/g OR protein-creatinine ratio ≥50 mg/g or dipstick protein ≥1+.
Participants are from Austria, DE, and IT
Participants are from Argentina, Austria, Brazil, Canada, Chile, CN, Costa Rica, Czech Republic, Denmark, France, DE, Hungary, IL, IT, JP, Malaysia, Mexico, NL, NZ, Peru, Portugal, Russia, SG, Slovakia, Spain, UK, US, Venezuela
Participants are from AU, CA, CN, Czech Republic, Estonia, France, DE, Hungary, India, Ireland, IT, Lithuania, Malaysia, NL, NZ, Philippines, Poland, Russia, Slovakia, UK
mean (standard deviation)